Benralizumab (MEDI-563) is an IL-5Rα-directed cytolytic monoclonal antibody that induces rapid, direct and nearly complete depletion of eosinophils via enhanced antibody-dependent cell-mediated cytotoxicity. It can be used for severe eosinophilic asthma.

1044511-01-4

MEDI-563;BIW-8405;Benralizumab